Key Highlights
- Femasys secured a $30 million private Placement led by new institutional investor Nantahala Capital, several times the company's market value, funding both its fertility commercial rollout and FemBloc's US regulatory pathway.
- Days after the raise closed, the company received its first patents covering the proprietary polymer at the core of FemBloc, its non-surgical permanent birth control device, spanning the US, Japan, South Korea, Brazil, India, and Europe.
- The financing roughly quadruples Femasys's share count before accounting for warrants, with milestone warrants structured to become exercisable specifically when quarterly Revenue reaches $1.5 million and the share price rises 30% above the exercise price.
Femasys Inc. (NASDAQ:FEMY) has spent 2026 running two races at once: proving its women's health devices can sell, and funding the clinical trial that could unlock its biggest market. In early August, the Suwanee, Georgia company made decisive progress on the second front.
On 7 August 2026 Femasys announced a $30 million private placement led by new institutional investor Nantahala Capital, a raise several times the company's own Market Value at the time. Four days later the deal closed. On 12 August it followed with the first issued patents covering the blended polymer at the heart of FemBloc, its non-surgical permanent birth control product.
For a micro-cap device developer that entered the quarter with roughly $5.4 million in cash and a runway stated only into the third quarter of 2026, that changes the near-term picture. But it comes with heavy dilution.
What Happened
The placement was priced at $3.20 per share of common stock and accompanying warrants, and $3.1999 for pre-funded warrants and accompanying warrants, covering 9,374,999 shares and pre-funded warrants. Each share purchased carries two warrants, a standard Warrant and a milestone warrant, together covering 18,749,998 shares, with a three-year term and a $2.95 exercise price.
The milestone warrants become exercisable only against defined triggers, tied to quarterly revenue of $1.5 million, a share price at 130% of the exercise price, and an effective registration statement. If every warrant is exercised, Femasys says potential proceeds reach up to $90 million. Rosalind Advisors and members of management invested alongside Nantahala; Laidlaw & Company (UK) Ltd. acted as placement agent.
Proceeds are earmarked for taking the fertility portfolio to OB/GYNs and fertility specialists and for advancing the FemBloc U.S. clinical and regulatory program. Lee-Sepsick said the financing substantially strengthens the Balance Sheet and provides runway to execute the business plan.
Why It Matters
FemBloc defines the long-term Investment case. It places a proprietary blended polymer into both fallopian tubes, where it degrades and leaves natural scar tissue that permanently blocks them: permanent contraception delivered in a doctor's office without surgery, incisions or general anaesthesia, unlike tubal ligation.
FemBloc already carries approvals in Europe, the United Kingdom and New Zealand, all granted during 2025. In the United States it remains investigational, and approval runs through the FINALE pivotal trial under an FDA Investigational Device Exemption, with a Premarket Approval, or PMA, submission to follow. PMA is the FDA's most demanding device pathway.
The Patent news plugs a gap. Femasys already held patents on the FemBloc delivery system; these are the first covering the polymer itself. They span the United States (No. 12606719), Japan, South Korea, Brazil, Hong Kong, India and a European patent validated across more than a dozen countries.
The Numbers
Femasys reported first-quarter 2026 sales of $424,889 on 8 May, up 24.5% from $341,264 a year earlier. The loss from operations was $4.22 million, though the company posted Net Income of $846,100 against a $5.9 million net loss a year earlier, a swing driven by non-operating items rather than trading. Research and Development spending fell 55.9% to $1.31 million as products moved into inventory.
Cash and equivalents stood at $5.4 million at 31 March 2026, down from $9.3 million at the end of 2025, with an accumulated Deficit of $145.0 million. For full-year 2025, sales were $2,293,313, up 40.8%, against a net loss of $18.6 million.
The dilution arithmetic is stark. Femasys had roughly 3.02 million shares outstanding in early August, following a 1-for-20 Reverse Stock Split effective 8 June 2026, and a Market Capitalisation under $10 million. Issuing about 9.37 million shares and pre-funded warrants roughly quadruples that count; full exercise of the 18.75 million warrants would take the diluted figure to many multiples of the pre-deal base.
What It Means for the Company
Cash was the binding constraint, and it has been loosened. Running a 401-patient pivotal trial while building a commercial salesforce is expensive, and at roughly $4 million of quarterly operating burn the pre-deal balance could not have funded both for long.
The Shareholder register also changes. Nantahala is a new institutional holder, Rosalind added to the book, and management participated. Newly appointed chief operating officer John Canning separately disclosed a purchase of 4,375 shares on 12 August.
Commercially, the strategy is to widen the funnel. FemaSeed Complete, launched at the ACOG meeting on 22 April and first used commercially on 5 May, bundles the FemaSeed intratubal insemination device with FemSperm sperm preparation so an OB/GYN can complete first-line fertility treatment in a single office visit. Femasys frames the addressable base as more than 40,000 OB/GYNs versus fewer than 2,000 infertility specialists.
Risks Investors Should Watch
Dilution is the headline risk. The share count expansion is severe, the warrants create a persistent overhang, and the milestone warrants are structured to be exercised precisely when the shares are performing well. The stock traded between roughly $2.29 and $2.66 in early August, below the $3.20 issue price.
Listing risk is recent history. Femasys used the June reverse split to cure a minimum bid price deficiency and regained compliance with Nasdaq Listing Rule 5550(a)(2) only on 24 June 2026.
Execution risk remains substantial. FINALE enrols 401 women, with an interim analysis once 300 have completed a year of use and follow-up running five years, so a U.S. FemBloc approval is not a near-term event. Revenue is still under half a million dollars a quarter, well below the $1.5 million quarterly milestone trigger.
What Comes Next
The immediate item is second-quarter 2026 results, which had not been released as of 14 August. That report should show cash at 30 June, before the raise landed, plus any updated runway guidance.
The markers thereafter: enrolment progress in FINALE, uptake of FemaSeed Complete among OB/GYN practices, international traction after April's Israeli market entry and the FemHSG catheter CE Mark granted on 13 May, and whether revenue converges on the $1.5 million quarterly milestone.
Conclusion
Femasys solved its most immediate problem, cash was running out just as its most expensive trial and commercial buildout were ramping up, but it did so at real cost to existing shareholders through a share count that roughly quadruples before any warrants are exercised. The new patents genuinely strengthen FemBloc's competitive position by covering the polymer itself rather than just the delivery system, closing a real intellectual-property gap. Whether the dilution proves worthwhile depends on execution across two fronts simultaneously: enrollment in the 401-patient FINALE trial, which won't read out for years, and whether FemaSeed Complete can push quarterly revenue toward the $1.5 million threshold that triggers the milestone warrants.






Please wait processing your request...